Merck, Pfizer Decorate Consumer Health 'For Sale' Signs With Strong Results
This article was originally published in The Pink Sheet
Executive Summary
Merck KGAA reports 11% growth in sales of its OTC lines over a year ago, but, like Pfizer, looks to sharpen its long-term focus on the Rx business.
You may also be interested in...
Reckitt Benckiser Gives Consumer Health Portfolio Its Own Home – What's Next?
UK manufacturer in January begins operating with a separate health care division, representing 60% of sales with products including Mucinex and Mead Johnson infant and adult formulas, and a home care/hygiene division led by Lysol disinfectants. The plan piques analysts' expectations that operating the divisions separately will lead to divesting one.
Pfizer Déjà Vu: Is It Time To Sell The Consumer Health Business?
As Pfizer re-examines a potential sale of its consumer business, analysts expect it would attract suitors for its unit, with $15bn to $17bn a likely price, but also say it might be better off continuing to compete in the sector that accounted for around $3.4bn of its 2016 revenues.
Big Pharma Set To Compete For German Merck's Consumer Health Unit
German Merck is seeking a buyer or partner for its consumer health unit, which brought in sales of €860m last year and includes big vitamin brands Seven Seas and Neurobion.